Alexion Pharmaceuticals, Inc. is a biopharmaceutical company working to develop and deliver life-changing drug therapies for patients with serious and life-threatening medical conditions. Alexion is engaged in the discovery, development and commercialization of therapeutic products aimed at treating patients with a wide array of severe disease states. Soliris is Alexion’s first marketed product. Soliris a first-in-class terminal complement inhibitor developed from the laboratory through regulatory approval and commercialization by Alexion. Soliris has been approved in the U.S., European Union, Japan and other countries as the first treatment for patients with PNH, an ultra-rare, debilitating and life-threatening blood disorder defined by chronic hemolysis, or the destruction of red blood cells. Prior to these approvals, there were no therapies specifically available for the treatment of patients with PNH. Alexion's innovative approach to complement inhibition has received some of the pharmaceutical industry's highest honors: the 2008 Prix Galien USA Award for Best Biotechnology Product with broad implications for future biomedical research and the 2009 Prix Galien France Award in the category of Drugs for Rare Diseases. More information on Soliris is available at www.soliris.net www.pnhsource.com www.alxn.com
Amgen discovers, develops, manufactures, and delivers innovative human therapeutics. A leader in biotechnology since 1980, Amgen was one of the first companies to realize the new science’s promise by bringing safe, effective medicines from lab, to manufacturing plant, to patient. Amgen therapeutics have changed the practice of medicine, helping millions of people around the world in the fight against cancer, kidney disease, rheumatoid arthritis, bone disease, and other serious illnesses. Amgen pioneered the development of novel products based on advances in recombinant DNA and molecular biology, and launched the biotechnology industry’s first blockbuster medicines. Today, as a Fortune 500 company serving millions of patients, Amgen continues to be an entrepreneurial, science-driven enterprise dedicated to helping people fight serious illness.http://wwwext.amgen.com/medpro/overview.html
Siemens Healthcare Diagnostics provides clinicians with a trusted portfolio of oncology assays that aid in the detection, monitoring, follow-up and management of cancer patients. Only Siemens can offer a core oncology menu combined with unique breast and prostate cancer tests that are trusted by the leading cancer centers and institutions worldwide to aid in the delivery of quality patient care. We help our customers better serve their clients through our comprehensive menu of in vivo and in vitro diagnostic tools and the promise of integrated diagnostics, a dedication to R&D investment and clinical trials, the development of key relationships with opinion leaders, and an ongoing focus on educational tools and symposia for the patient, laboratory and physician.